Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates [Yahoo! Finance]
Passage Bio (PASG) is now covered by Wedbush. They set a "reduce" rating on the stock.
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Passage Bio (PASG) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $30.00 price target on the stock.
Passage Bio (PASG) had its price target lowered by Canaccord Genuity Group Inc. from $67.00 to $23.00. They now have a "buy" rating on the stock.